BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Amlypave (Anselamimab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Amlypave (Anselamimab)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07615270-11165@assetmemo.bio
DTSTAMP:20261121T004103Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Amlypave (Anselamimab): Phase 1 readout est. (NCT07615270)
DESCRIPTION:Amlypave (Anselamimab)\, phase 1\, AL Amyloidosis.\nStudy: A Pi
 lot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tis
 sue Involvement\nEstimated primary completion: July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/anselamimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07615270
URL:https://assetmemo.bio/drug/anselamimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
